For COVID-19 and vaccination updates, view our information for the community. If you're experiencing symptoms, call your primary care provider.

Decorative dot pattern background image.
Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image.

NRG GY014

Trial Overview

Official Title

A phase II study of tazemetostat (EPZ-6438) (IND#138671) in recurrent or persistent endometrioid or clear cell carcinoma of the ovary, and recurrent or persistent endometrioid endometrial adenocarcinoma

Study Purpose

To find out if this approach is better or worse than the usual approach for your ovarian or endometrial cancer. 

Diagnosis

Pathologically proven diagnosis of recurrent or persistent ovarian endometrioid or clear cell carcinoma, OR recurrent or persistent endometrioid endometrial adenocarcinoma.

Eligibility

Must have completed prior therapy anywhere from 14 days to 6 weeks before registration depending on which therapy regimen was assigned.

Patients must sign an approved informed consent and authorization permitting release of personal health information.

Intervention

  • Tazemetostat 800 mg (4 tablets by mouth two times a day) until disease progression or unacceptable toxicity.  
  • Patients must keep a pill diary.

Follow ups occur every 3 months for 2 years and then every 6 months for 3 years (5 years total).

For more information, visit ClinicalTrials.gov

Key Participation Requirements
Gender
Female
Age
19 years and older
Phase
Phase II
Methodist Health System Trial Code
GY014